Back to search

National and Kapodistrian University of Athens

Η αντιμετώπιση της πνευμονικής υπέρτασης σε καρδιοχειρουργικούς ασθενείς υψηλού κινδύνου με τη χρήση εισπνευστικών και ενδοφλέβιων παραγόντων

Abstract

dc:description

Pulmonary hypertension (PH) is a serious prognostic factor for increased morbidity and mortality in cardiac surgery patients, mainly due to its association with right heart failure. PH is defined as a pathological increase in mean pulmonary artery pressure and may arise through various pathophysiological mechanisms. The most common form of PH in cardiac surgery patients is that related to left heart disease, although the incidence of other types of PH is increasing, particularly due to population aging and multimorbidity. During cardiac surgical procedures, PH may worsen due to several factors such as the inflammatory response associated with cardiopulmonary bypass (CPB), ischemiareperfusion injury, and protamine administration, leading to right ventricular dysfunction. Perioperative right heart failure is associated with high mortality and prolonged hospitalization. Its management is a clinical challenge, as there are no clear treatment guidelines. The main goals are to reduce right ventricular afterload and enhance its contractility. Milrinone and levosimendan are two pharmacological agents used in the management of PH and right heart failure. Milrinone, a phosphodiesterase type 3 inhibitor, has inotropic and vasodilatory effects. However, intravenous administration of milrinone often causes hypotension. To avoid systemic arterial hypotension, inhaled administration of milrinone offers an alternative route of administration. Similarly, levosimendan is an inotropic agent that increases myocardial sensitivity to calcium and enhances myocardial contractility without increasing metabolic demand, while also exhibiting cardioprotective properties. The present study investigates the pharmacodynamic effects of levosimendan in patients with pre-existing PH undergoing cardiac surgery with the use of CPB. It is a randomized study comparing the intravenous administration of levosimendan with the inhaled administration of milrinone in cardiac surgery patients with pre-existing PH, aiming to prevent the worsening of PH development of right ventricular failure. The results of the study show that both drugs have a protective effect by reducing pulmonary artery pressure. However, intravenous administration of levosimendan at a dose of 6 mcg/kg, prior to CPB, results in stronger and longer-lasting pulmonary vasodilation compared to inhaled milrinone. Therefore, levosimendan may serve as a useful therapeutic tool in the perioperative management of PH, although further studies are required to fully evaluate its efficacy.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ftikos, Panagiotis
  • Φτίκος, Παναγιώτης

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60532

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ftikos, Panagiotis; Φτίκος, Παναγιώτης. Η αντιμετώπιση της πνευμονικής υπέρτασης σε καρδιοχειρουργικούς ασθενείς υψηλού κινδύνου με τη χρήση εισπνευστικών και ενδοφλέβιων παραγόντων. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/60532